Financing is the fuel that drives growth in the biopharma sector, and participants at the BIO Asia-Taiwan Conference 2021 this week discussed different financing strategies for companies in the currently booming market.
The complete relegation of conferences to cyberspace that began with one HIV conference, CROI 2020, ended with another, the 2021 IAS meeting. Though the conference was still largely virtual, there was also an in-person component held in Berlin.
Multiple companies are pursuing CD47-blockade as a tumor immunotherapy approach. Sana Biotechnology Inc., too, is interested in the therapeutic potential of CD47 – but from a very different angle. By overexpressing CD47 on stem cells, researchers at Sana want to make transplanted cells invisible to the immune system.
New and updated preclinical and clinical data presented by biopharma firms at the 81st Scientific Sessions of the American Diabetes Association, including: Astrazeneca, Boehringer, Diabetology, Eiger, Eli Lilly, Novo, Remd, Scohia.
New and updated preclinical and clinical data presented by biopharma firms at The International Liver Congress – The Annual Meeting of the European Association for the Study of the Liver, including: Arbutus, Arrowhead.
Sometimes, scientific progress comes from conceptual insights that arrive in a flash. More often, however, such progress arrives in a decidedly less glamorous, though no less important, manner – through the development of new technologies in what can be a very slow iterative cycle of getting a new method to work.
New and updated preclinical and clinical data presented by biopharma firms at The International Liver Congress – The Annual Meeting of the European Association for the Study of the Liver, including: Antios, Arrowhead, Assembly, Brii, Durect, Enanta, Mirum.
About a year-and-a-half after the sequencing of the SARS-CoV-2 virus and the onslaught of COVID-19 therapeutic and vaccine development that followed, the biopharma industry boldly tackles a slew of ongoing issues from vaccine hesitancy and supply inequities to the ramifications of a potential intellectual property waiver and the pressing need to prepare global systems for the next pandemic.
As debate continues to rage over the approval and pricing of the Alzheimer’s disease therapy Aduhelm (aducanumab), Biogen Inc. CEO Michel Vounatsos said his firm is “taking a position that is very responsible” but has “yet to be understood out there, and we have to do a better job.”
Johnson & Johnson’s Janssen Cilag Ltd. pharma unit has phase III data from its project combining the oral blood cancer drug Imbruvica (ibrutinib) with its blockbuster rival, Venclexta (venetoclax), in chronic lymphocytic leukemia (CLL), which could give it an edge over competitors in the space.
RSS
